- Alpha Cognition (CSE:ACOG) has been awarded a $750,000 grant from the Army Medical Research and Materiel Command
- The grant is for a pre-clinical study to use ALPHA-1062 intranasally to reduce blast mild traumatic brain injury induced functional deficit and brain abnormalities
- The pre-clinical study is expected to begin in early Q4 2023 and continue for 16 months
- Alpha Cognition Inc. (ACOG) opened trading at $0.22 per share
Alpha Cognition (CSE:ACOG) has been awarded a $750,000 grant from the Army Medical Research and Materiel Command.
The grant is for a pre-clinical study to use ALPHA-1062 intranasally to reduce blast mild traumatic brain injury induced functional deficit and brain abnormalities.
The study grant will be conducted in collaboration with the Seattle Institute for Biomedical and Clinical Research and is endorsed by Department of Defense. It will evaluate the efficacy of ALPHA-1062IN in reducing the adverse effects of repetitive blast-induced mild traumatic brain injury in pre-clinical models.
A blast injury in military personnel happens when a soldier is exposed to the powerful forces generated by explosions, such as bombs or improvised explosive devices.
ALPHA-1062IN is a promising drug candidate that has shown potential for the treatment of mild traumatic brain injury.
The research program will evaluate ALPHA-1062’s ability to reduce a toxic form of a brain protein [Tau] known to be increased in this military relevant brain injury model.
Denis Kay, the study PI and Alpha Cognition’s Chief Scientific Officer, explained that the body of evidence is growing to show that people who have suffered a mild traumatic brain injury, are at greater risk of developing dementia in later life and are at risk for additional neurocognitive issues.
“Accumulation of toxic Tau in the brain is linked to dementia progression and was previously shown to be decreased by ALPHA-1062 in a separate pre-clinical model of moderate traumatic brain injury. We are excited to embark upon a trial to provide additional evidence for reduction of one of the neuropathological drivers of increased dementia risk.”
The pre-clinical study is expected to begin in early Q4 2023 and continue for 16 months.
Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases. The company recently reported financial results for Q1 2023. Click here to read more.
Alpha Cognition Inc. (ACOG) opened trading at $0.22 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
